Journal of Chemical and Pharmaceutical Research (ISSN : 0975-7384)

header
Reach Us reach to JOCPR whatsapp-JOCPR +44 1625708989
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Original Articles: 2015 Vol: 7 Issue: 5

Antiatherogenic effect of Mezzetia parviflora BECC. extract in high cholesterol fed rats

Abstract

The investigation of anti-atherosclerotic activity of M. parviflora and the mechanisms responsible for the extract’s effects (antihypolipidemic, anti-lipidperoxidation, and monocyte chemoattractant protein-1 (MCP-1) inhibition activities) has been performed. In this study, atherogenesis was induced by feeding rats with a hypercholesterolemic diet (200 mg/Kg day-1) for 3 months. The cholesterol intake was administered along with simvastatin 3.6 mg/Kg or M. parvifloraextract at doses of 100, 300 and500 mg/Kg.Atheroma observation was performed by immunohistochemistry staining method with anti-macrophage antibody (MAC387). Animal plasma biochemical (total cholesterol, trigliserida, HDL, LDL, malondialdehyde, and MCP-1) profiles were measured. M. parvifloraextract dose dependently decreased the total-cholesterol, triglyceride, and LDL-cholesterol levels; and increased HDL-cholesterol in atherogenic-diet rats. Furthermore, M. parvifloraextract lowered the lipidperoxidation (malondilaldehyde, MDA) and MCP-1 production in dose dependent manner. Immunohistochemistry staining with anti-macrophage antibody(MAC387) showed that atherogenic-diet rats treated with M. parvifloraextract at a dose of 500 mg/Kg was not colored positively, the same as that in normal and simvastatin treated groups. These results suggest that M. parviflora-standardized extract may have anti-atherosclerosis effect throughantihiperlipidemia and antilipid-peroxidation activities.